Skip to main content
Premium Trial:

Request an Annual Quote

UK Startup Paradigm Therapeutics Signs Drug Target Deal with Medavir

 

NEW YORK, Dec. 13 - Paradigm Therapeutics, of Cambridge, UK, has signed a three-year collaboration with Swedish biopharma Medavir, to discover new protease drug targets, the company said Friday.

 

Paradigm, a spinout from the Universityof Cambridge, uses transgenic mouse technology, along with bioinformatics and other molecular biology methods, to determine the biological function of novel human proteins encoded by the genome, in order to find new drug leads. Earlier this week, the company raised £12 million ($19.1 million) in a second round of private financing.

 

Medavir, of Huddinge, Swedenand Cambridge, UK, will offer its protease inhibitor drug discovery know-how, and its compound libraries, to the collaboration.

 

The partners plan to identify up to six novel proteases, and develop small-molecule protease inhibitor drugs, for either commercialization or out licensing.   They did not disclose financial terms of the agreement.

The Scan

Follow-Up Data Requests to Biobank Participants Ineffective, Study Finds

An effort to recontact biobank enrollees for additional information reports low participation in a new BMJ Open study.

Study Finds Widespread Transmission of Resistant Bacteria in Vietnam Hospitals

A sequencing study in The Lancet Microbe finds widespread transmission of drug-resistant Escherichia coli, Klebsiella pneumoniae, and Acinetobacter baumannii in two Vietnam ICUs.

Novel Brain Cell Organoids Show Promise for Autism Research

University of Utah researchers report in Nature Communications on their development of brain cell organoids to study SHANK3-related autism.

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.